Preclinical evaluation of a Haemophilus influenzae type b conjugate vaccine process intended for technology transfer - Wikidata - wikimedia - TriplyDB

Preclinical evaluation of a Haemophilus influenzae type b conjugate vaccine process intended for technology transfer

Preclinical evaluation of a Haemophilus influenzae type b conjugate vaccine process intended for technology transfer

http://www.wikidata.org/entity/Q35498252

about

Preclinical evaluation of a Haemophilus influenzae type b conjugate vaccine process intended for technology transfer

http://www.wikidata.org/entity/Q35498252

description

2014 nî lūn-bûn

@nan

2014 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Preclinical evaluation of a Ha ...... tended for technology transfer

@ast

Preclinical evaluation of a Ha ...... tended for technology transfer

@en

type

label

Preclinical evaluation of a Ha ...... tended for technology transfer

@ast

Preclinical evaluation of a Ha ...... tended for technology transfer

@en

prefLabel

Preclinical evaluation of a Ha ...... tended for technology transfer

@ast

Preclinical evaluation of a Ha ...... tended for technology transfer

@en

P1433

Q35498252-BC8B30DF-3D52-4A28-B854-DB6B17B85C54

P1476

Q35498252-1692AAA2-10B2-47BA-9A21-8E4411E97F5E

P2093

Q35498252-0DF59A8F-3C17-453D-A224-E92511D17D28

Q35498252-37EB8026-A0B6-43E3-B8B1-D1BC0F3DC82E

P2860

Q35498252-01AE9E33-2172-4044-9279-0FE9272E0AA9

Q35498252-2B7E7B3B-2297-4EC1-9320-BC02EB1ED72B

Q35498252-422629D5-DD59-4DC2-98AC-2E40E36B076D

Q35498252-500F94DF-9F95-48FF-8756-62BAE2B71985

Q35498252-662D9E0A-1800-4C6F-B855-2967D14B957D

Q35498252-9819AAE3-8DD6-4635-B970-5EA8A2D72E3C

Q35498252-B4E0C612-DD97-4257-86A9-4C0D5C91C8E5

Q35498252-CC55C692-E8A7-440F-810C-0606CBC6A5A5

Q35498252-E65A3694-249D-4E22-B799-A338699B140C

Q35498252-F4E2AF29-9030-446F-BE50-62361DDD9A99

P304

Q35498252-492B012A-E9CB-4248-8FD6-0CA8D618EB15

P31

Q35498252-824744F4-5D11-4E72-8EC7-39CAE848D587

P356

Q35498252-AEEDE07D-9426-412E-AA63-10EC0D0A9CF5

P433

Q35498252-8AC6743E-A2AE-432A-8F1B-977A9BF1E8BB

P478

Q35498252-8D6E32C9-F394-4E31-84AE-A11157C11A9A

P50

Q35498252-512FACCD-7554-43CC-B4F5-A066E3AF9EA1

P577

Q35498252-BC03E75E-CC24-4C17-B37F-C5CC0F9339A1

P5875

Q35498252-95C6FF49-E1AD-458A-9170-248B19718772

P698

Q35498252-770EE26E-3A31-44CE-A7C5-98F4C8A4CEE4

P932

Q35498252-A95DDDA9-D959-4BD6-95F6-6CC0A56D99B2

P356

P1433

Human Vaccines & Immunotherapeutics

P1476

Preclinical evaluation of a Ha ...... tended for technology transfer

@en

P2093

Ahd Hamidi

http://www.w3.org/2001/XMLSchema#string

Hans Kreeftenberg

http://www.w3.org/2001/XMLSchema#string

P2860

Evaluation of a guinea pig model to assess interference in the immunogenicity of different components of a combination vaccine comprising diphtheria, tetanus and acellular pertussis (DTaP) vaccine and haemophilus influenzae type b capsular polysacch

Development of a guinea pig model to assess immunogenicity of Haemophilus influenzae type b capsular polysaccharide conjugate vaccines.

Development and technology transfer of Haemophilus influenzae type b conjugate vaccines for developing countries.

The Developing Countries Vaccine Manufacturers' Network (DCVMN) is a critical constituency to ensure access to vaccines in developing countries.

Further studies on the immunogenicity of Haemophilus influenzae type b and pneumococcal type 6A polysaccharide-protein conjugates

Enhancement of serum and mucosal immune responses to a Haemophilus influenzae Type B vaccine by intranasal delivery.

Antigenicity and immunogenicity of a synthetic oligosaccharide-protein conjugate vaccine against Haemophilus influenzae type b.

Preclinical studies on a recombinant group B meningococcal porin as a carrier for a novel Haemophilus influenzae type b conjugate vaccine.

Safety and immunogenicity of an indigenously developed Haemophilus influenzae type b conjugate vaccine through various phases of clinical trials.

Immunogenicity and safety of an indigenously manufactured reconstituted pentavalent (DTwP-HBV+Hib) vaccine in comparison with a foreign competitor following primary and booster immunization in Indian children.

P304

2691-2696

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4161/HV.28924

http://www.w3.org/2001/XMLSchema#string

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

10

http://www.w3.org/2001/XMLSchema#string

P50

Pauline Verdijk

P577

2014-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

262023440

http://www.w3.org/2001/XMLSchema#string

P698

25483504

http://www.w3.org/2001/XMLSchema#string

P932

4977440

http://www.w3.org/2001/XMLSchema#string